Voglibose 0.2 mg (Generic)

Product Overview

Voglibose 0.2 mg is a generic oral antidiabetic medication manufactured by Abbott India Pvt Ltd. It belongs to the class of alpha-glucosidase inhibitors and is specifically indicated for the treatment of type 2 diabetes mellitus. The product is supplied in strips containing 30 tablets, with pack sizes available in 30, 60, or 90 tablets. Each tablet delivers 0.2 mg of voglibose, a compound that helps control post-prandial glucose spikes by slowing carbohydrate absorption in the small intestine. This medication is intended for adult patients who require additional glycemic control alongside diet and exercise.

What Is Voglibose?

Voglibose is a synthetic oligosaccharide derivative that inhibits the enzyme alpha-glucosidase, which is responsible for breaking down complex carbohydrates into glucose. By delaying the hydrolysis of starches, voglibose reduces the rate at which glucose enters the bloodstream, leading to a more gradual rise in blood sugar after meals. The drug is marketed under the brand name Diabinese among others, but the generic version produced by Abbott India contains the same active ingredient and therapeutic effect.

Uses and Benefits

The primary use of voglibose is to improve glycemic control in adults with type 2 diabetes who have not achieved adequate glucose levels with diet and exercise alone. Clinical studies have demonstrated that voglibose can lower post-prandial hyperglycemia, reduce HbA1c modestly, and decrease the frequency of glucose excursions. Patients often experience fewer episodes of hypoglycemia compared with sulfonylureas, making it a safer option for those sensitive to low blood sugar. Additionally, voglibose has been shown to improve lipid profiles by modestly reducing triglycerides, which can be beneficial for patients with concomitant metabolic syndrome.

How It Works

Voglibose acts by competitively inhibiting alpha-glucosidase enzymes located in the brush border of the small intestine. This inhibition slows the breakdown of dietary carbohydrates into glucose, leading to a delayed and reduced post-prandial glucose peak. The drug does not affect insulin secretion or action, which distinguishes it from other antidiabetic agents. Its mechanism is confined to the gastrointestinal tract, meaning systemic absorption is minimal and the risk of drug-drug interactions is low.

Dosage Guidelines

Voglibose is typically initiated at a dose of 0.2 mg taken orally with the first bite of each main meal. The dosage may be titrated based on the patient’s response and tolerability, with a maximum recommended daily dose of 0.6 mg (three tablets) divided across meals. Adjustments are recommended for patients with renal impairment or those taking other medications that affect carbohydrate metabolism. It is essential that patients follow the prescribing clinician’s instructions and do not alter the dose without medical supervision. For comprehensive dosing information, refer to the official prescribing information available at the FDA label.

Side Effects

Like all medications, voglibose can cause adverse effects. The most commonly reported side effects include gastrointestinal disturbances such as flatulence, abdominal discomfort, and diarrhea. These events are generally mild to moderate and often resolve with continued use. Less frequent but more serious adverse reactions may involve hepatic enzyme elevations, which typically manifest as yellowing of the skin or eyes (jaundice). Patients should discontinue the medication and seek medical attention if they experience persistent abdominal pain, severe diarrhea, or signs of liver dysfunction. For detailed safety data, consult the Drugs.com monograph.

Warnings and Precautions

Patients should inform their healthcare provider of any history of liver disease, kidney disease, or gastrointestinal disorders before starting voglibose. Caution is advised in individuals with a known hypersensitivity to voglibose or any of its excipients. The medication should not be used in patients with type 1 diabetes or in those with a history of diabetic ketoacidosis. Pregnant and breastfeeding women should only use voglibose if the potential benefit justifies the potential risk, and they must discuss this with their physician. Additionally, patients taking other antidiabetic agents should monitor blood glucose closely to avoid hypoglycemia when transitioning between therapies.

FAQs

1. What is the recommended starting dose of voglibose? The usual starting dose is 0.2 mg taken with the first bite of each main meal. The dose may be increased gradually based on clinical response.

2. Can voglibose be used in combination with metformin? Yes, voglibose can be prescribed alongside metformin or other oral hypoglycemic agents, but dosage adjustments and glucose monitoring are recommended to prevent hypoglycemia.

3. How long does it take for voglibose to lower blood sugar? The effect on post-prandial glucose begins within one hour after ingestion, with maximal benefit observed 2–3 hours after meals.

4. Is voglibose safe for patients with kidney impairment? Dose adjustments are necessary for patients with moderate to severe renal impairment. Consult a healthcare professional before use.

5. Where can I find the full prescribing information? The complete FDA-approved prescribing information is available at the FDA Drug Database and on the manufacturer’s website.

For additional medical guidance, reputable resources such as the MedlinePlus and the NIH provide evidence-based information on diabetes management.

Related Products

• Phenergan 10 Mg (Promethazine)
• Adiza 10 mg (Ilaprazole)
• Hydroquinone 4% Cream (Generic)
• Melalite Forte Cream (Hydroquinone)
• Faceclin AT Gel (Adapalene/Clindamycin)
• Okamet 500 Mg (Metformin)
• Cremagel (Diltiazem)
• Diltiazem Gel (Generic)
• Calaptin 40 mg (Verapamil)
• Calaptin 40 mg
• Sorbitrate (Isosorbide Dinitrate)
• Calaptin SR 120 mg (Verapamil)